SwRI will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, Booth 1315. For more information, please contact Robert Gutierrez.
We offer full-range services for CGMP pharmaceutical, bioengineering, and medical device technologies. We specialize in drug discovery, drug development, in silico docking, method and process development, pilot synthesis, extrusion and microencapsulation.
Tuesday, Nov. 5
3:30 p.m. – 4:30 p.m.
“Development of Implantable Malaria Chemoprophylaxis” Robert Gutierrez
Successful prevention of malaria is highly dependent on compliance with a prescribed daily chemoprophylaxis regimen. However, maintaining drug compliance by U.S. service members can be difficult due to a daily oral dosing requirement, side effects such as nausea and photosensitivity, organizational culture, command emphasis, and the demands of the operational environment. A current scientific collaboration between Titan Pharmaceuticals (Titan), the Experimental Therapeutics (ET) Branch at Walter Reed Army Institute of Research (WRAIR), and Southwest Research Institute (SwRI) has been established to develop long-term, controlled-release, implantable anti-malarial formulations.
SwRI's Pharmaceutical Development Department
Stop by Booth 1315 Nov. 3-6 at the Henty B. Gonzalez Convention Center or visit us on the web to learn how we are supporting the pharmaceutical industry with analytical, regulatory and consultation services, including: